

The evolving clinical picture of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): A look at 1310 patients over 16 years

R. Christopher Doiron, MD¹; Dean A. Tripp, PhD^{1,2}; Victoria Tolls, MD¹; J Curtis Nickel, MD, FRCSC¹

¹Department of Urology, Queen's University; ²Department of Psychology, Queen's University, Kingston, ON, Canada

Cite as: *Can Urol Assoc J* 2018;12(6):196-202. <http://dx.doi.org/10.5489/cuaj.4876>

Published online February 23, 2018

Abstract

Introduction: Two decades of increasing understanding of etio-pathogenesis and clinical phenotyping produces an impression the clinical face of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is changing. We sought to retrospectively analyze trends in CP/CPPS patients presenting to our clinic for evaluation over a 16-year period.

Methods: Patients with CP/CPPS presenting to a tertiary clinic were evaluated prospectively from 1998–2014 with Chronic Prostatitis Symptom Index (CPSI) and UPOINT (urinary, psychosocial, organ-specific, infection, neurogenic, and tenderness) categorization. Patients were stratified in four cohorts, based on year of presentation, and we retrospectively analyzed variations in symptom scores and patterns, UPOINT categorization, and treatment modalities amongst cohorts.

Results: Mean age of the 1310 CP/CPPS patients was 44.7 years, while mean CPSI pain, urination, and total scores were 10.6, 4.8, and 23.3, respectively. The most prevalent UPOINT domain, urinary (U) (71.8%) was associated with a higher CPSI urination score (6.3), more frequent penile tip pain (37%), dysuria (48%), and more treatment with alpha-blockers (70%). Increase in UPOINT domains was associated with higher CPSI pain, quality of life (QoL), and total scores. Trends over time included increased prevalence of psychosocial (P), organ (O), and tenderness (T) domains, as well as increased use of alpha-blockers, neuromodulation, and phytotherapy as treatment modalities. There was little variation in age, CPSI scores, and pain locations over time.

Conclusions: The changing clinical face of CP/CPPS reflects the increased recognition of psychosocial (P domain) and pelvic floor pain (T domain), along with the concomitant use of associated therapies. There was little variation of pain/urinary symptom patterns and QoL.

Introduction

Prostatitis syndromes, including prostate pain complaints among men, have long been recognized as a common clinical scenario encountered by physicians.^{1,2} It took several years of concerted effort from the National Institutes of Health (NIH) via their Chronic Prostatitis Collaborative Research Network (CPCRN) to help define the disease of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). International consensus following a 1995 chronic prostatitis workshop classified CP/CPPS into four categories^{3,4} — this helped define the disease for clinicians, provided a framework from which to approach a disease with a challenging, heterogeneous presentation, and furthermore, allowed for a more standardized approach to research in the field.

The continued enthusiasm of the NIH collaboration led to the development of a validated symptom index tool⁵ — the NIH Chronic Prostatitis Symptom Index (CPSI) — which has allowed for objective evaluation of patients and their response to treatment.

This tool has proved invaluable in evaluating various treatments for CP/CPPS in clinical trials,^{6–8} has proved helpful in evaluating CP/CPPS prevalence,⁹ and has been used to validate tiers of disease severity.¹⁰

Despite these advancements, CP/CPPS remained a difficult entity to manage. Randomized controlled trials of various treatment modalities failed to show significant improvements in measured outcomes.¹¹ Furthermore, the etiology and pathogenesis of CP/CPPS remained an enigma and likely represented a constellation of disease contributors and pathways. There were, however, some subgroups that appeared to benefit from various treatment modalities.^{11,12} It was becoming accepted that the heterogeneous nature of patients presenting with CP/CPPS would be best evaluated by subgrouping patients according to either mechanisms, biomarkers, or symptoms. Using available clinical assessment, a phenotypic approach to classifying patients in clinical practice was proposed. UPOINT phenotyping¹³ built on the improvements made by the NIH classification by further recognizing that even within these four broad categories, patients were still heterogeneous. Assessing individual

patients according to the proposed six domains allowed for improved patient-centred care, leading to development of individualized clinical treatment strategies.¹⁴

It has now been close to two decades since our updated classification system came into general use and a decade since UPOINT was first introduced, and this has led to a plethora of current research in the field. But have any of these developments made an impact on patient evaluation and subsequent treatment?

This study is a retrospective look at CP/CPPS patients evaluated in a single outpatient clinic over the course of a 16-year period, beginning with introduction of our current classification system and spanning the introduction of UPOINT phenotyping. We were interested in observing the initial presentation of CP/CPPS patients in a tertiary prostatitis clinic to determine changes in symptom patterns, UPOINT phenotype, and treatment modality trends over time.

Methods

Participants and study design

This study is a retrospective examination of a cohort of CP/CPPS patients examined at a single outpatient clinic. The cohort was examined as part of a large, prospective clinical quality assurance database and was examined by a single urologist (JCN). The evaluation of this patient population has been described in previous publications.⁶ Data presented was collected from initial presentation between the years 1998–2014. This study was done under ongoing IRB approval for continued quality assurance with all patient data de-identified before analysis.

Measures

Data regarding the patients' demographics, symptom duration, CPSI scores (pain, urinary, impact/quality of life [QoL]), and UPOINT scoring were collected through initial evaluations at the CP/CPPS outpatient clinic (UPOINT scoring was retrospective prior to 2009 and prospective from 2009). Data regarding treatments received, therefore, represent interventions prior to initial evaluation at CP/CPPS clinic and would have been administered by referring physicians. Data was examined first as an overall cohort and then over time in four separate cohorts ranging from 1998–2001, 2003–2005, 2006–2009, and 2010–2014.

Data analysis

Statistical analysis was completed using Microsoft Excel 2010 Data Analysis package and the online Social Science Statistics software (<http://www.socscistatistics.com>).

Continuous variables (age and CPSI scores) were analyzed using ANOVA (using R version 3.3.1), with $p < 0.05$ regarded as significant. Categorical variables (UPOINT, pain locations, and treatments) were analyzed using Chi-squared test for trend in proportions (using R version 3.3.1), with $p < 0.05$ regarded as significant.

Results

Between the years of 1998–2014, 1349 patients with CP were evaluated at a single tertiary referral outpatient clinic. Of these, 39 patients were diagnosed with bacterial prostatitis (Category II) and were excluded from the current analysis. The remaining 1310 patients were given a diagnosis of Category III CP/CPPS. The majority of patients ($n=804$, 61.4%) were referred by a general practitioner, while 474 (36.2%) patients were referred by another urologist. Mean age of the 1310 CP/CPPS patients was 44.7 years (Table 1). Their mean CPSI pain, urination, QoL and total scores were 10.6, 4.8, 7.9, and 23.3, respectively (Table 1).

Overall, the most prevalent UPOINT domain was the urinary (U) domain ($n=941$, 71.8%), followed by organ-specific (O) ($n=660$, 50.4%), tenderness (T) ($n=644$, 49.2%), infection (I) ($n=440$, 33.6%), neurologic (N) ($n=402$, 30.7%), and psychosocial (P) ($n=361$, 27.6%) domains (Table 1). Positive reporting of the urinary domain was associated with a higher CPSI total score (25.8), higher CPSI urination score (6.3), more frequent penile tip pain ($n=348$, 37%), more frequent dysuria ($n=454$, 48.2%), and treatment with alpha-blockers ($n=659$, 70%) (Supplementary Table 1). Those patients who reported in the P domain were associated with a higher UPOINT total score (3.3) and were more commonly treated with antidepressants ($n=105$, 29.1%) and gabapentinoids ($n=37$, 10.2%) compared with the other domains (Supplementary Table 1).

An increased reporting of total UPOINT domains was associated with higher CPSI pain score (14.3), worse QoL (10.9), and higher total CPSI scores (31.4) (Supplementary Table 2). Pain location was not associated with severity of disease, nor was it associated with UPOINT domain or treatment modality (Supplementary Table 3).

An analysis of trends over time through examination of the four separate time cohorts revealed an increased prevalence of P domain ($p=0.0009$), O ($p \leq 0.0001$), and T ($p \leq 0.0001$) (Table 2). A decrease in the I domain ($p \leq 0.0001$) over time was also noted (Table 2). In terms of treatment modalities, there was an increased prevalence of use of alpha-blockers ($p \leq 0.0001$), neuromodulation ($p \leq 0.0001$), and phytotherapy ($p=0.0001$) with time, while the use of antibiotics — which ranged from 20.5–27.2% among the cohorts — did not change significantly with time (Table 2). There was little variation in age, CPSI scores, and pain locations over time.

Table 1. Age, CPSI scores, UPOINT analysis, pain locations, and treatments provided by referring physicians for 1310 CP/CPPS patients evaluated in a single outpatient clinic from 1998–2014

	1998–2014
	n=1310
Age	44.7 (\pm 13.3)
CPSI pain	10.6 (\pm 4.9)
CPSI urination	4.8 (\pm 3.1)
CPSI QoL	7.9 (\pm 3.1)
CPSI total	23.3 (\pm 9.0)
UPOINT	
U	941 (71.8%)
P	361 (27.6%)
O	660 (50.4%)
I	440 (33.6%)
N	402 (30.7%)
T	644 (49.2%)
Pain location	
Perineum	788 (60.2%)
Testicular	658 (50.2%)
Tip of penis	441 (33.7%)
Pubic/bladder	798 (60.9%)
Urination	553 (42.2%)
Ejaculation	615 (46.9%)
Treatment by referring physician*	
Alpha-blockers	806 (61.5%)
Antidepressants	198 (15.1%)
Quercetin	449 (34.3%)
QUrol	115 (8.8%)
Gabapentinoids	79 (6.0%)
Acupuncture/acupressure	10 (0.8%)
Physiotherapy	33 (2.5%)
Antibiotics	293 (22.4%)
Prostate massage	43 (3.3%)

*Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic. CPSI: Chronic Prostatitis Symptom Index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).

Discussion

We describe the change in specific CP/CPPS symptoms (CPSI scoring), clinical phenotypes (as expressed by UPOINT), and the correlation between these parameters over time in this retrospective study of 1310 CP/CPPS patients presenting to a single clinic over a 16-year period. The analysis confirmed that an increased number of UPOINT domains was associated with increased CPSI scores, as previously suggested by Shoskes et al.¹² It further showed that referring physicians tailored treatments to clinical presentation before UPOINT was described. It appears that both before and after UPOINT introduction, physicians were treating patients with urinary symptoms (U domain) with alpha-blockers, using antide-

pressants with secondary pain modulation in patients with psychological problems (P domain), neuromodulatory medications (gabapentinoids) for neurogenic pain (N domain), and increasing use of physiotherapy for pelvic floor pain (T domain). Although many patients, particularly in the earlier cohorts, were identified with infection at some time in their past (I domain), our observation of a trend of less antibiotics being employed over time for these patients was compatible with increased understanding of the inappropriateness of antimicrobial therapy in the majority of CP/CPPS patients.

We were surprised that patient-identified pain locations (CPSI) did not necessarily correlate with total CPSI score, UPOINT domains, or treatment. This is in keeping with a large, multinational study of 1563 CP/CPPS patients by Wagenlehner et al,¹⁰ where they found that pain severity and frequency were more important than pain location. CP/CPPS is a heterogeneous disease, and pain location may not be overly useful in helping direct treatment, i.e., pain is pain, regardless of location.

We observed a number of trends in UPOINT domain prevalence over time, specifically an increase over time in the P and T domains. This likely does not reflect a change in patient population presenting characteristics, but rather our referring physicians' understanding of the importance of identifying these domains for better treatment outcomes. In fact, it appears that the patients are not changing over time. The age, CPSI score (and pain, urinary, and impact/QoL subscores), and pain locations did not appreciably change from 1998–2014.

The low use of antibiotics (22.4% overall) was interesting to note, given that current guidelines, acknowledging the generally poor evidence for use in Category III CP/CPPS patients, recommend or suggest consideration of a course of antimicrobial therapy as a first-line treatment option.^{15–17} Although no trends in antibiotic use were seen over time, their relatively low usage as a treatment modality may reflect an increased attention to antimicrobial stewardship among general practitioners. This is in contrast to the increased trend over time in usage of neuromodulation and phytotherapy. This could similarly reflect an increased comfort among general practitioners with neuromodulatory medication prescribing, while increased use of phytotherapy may illustrate a patient population increasingly interested in seeking alternative health strategies and natural products.

While it is encouraging to note that referring physicians appeared to be embracing specific treatments towards identified phenotypes prior to referral to our specialty clinic, it is difficult to know if this has made a significant difference to patient outcome. Certainly, even with the described treatment identified in this referral population, baseline symptoms were similar to those of patients being enrolled in clinical treatment trials.¹¹ Further research will attempt to determine whether identification of specific phenotypes,

Table 2. Trends observed over time in 1310 CP/CPPS patients stratified by time of initial presentation to chronic prostatitis clinic

	1998–2001 n=195	2002–2005 n=387	2006–2009 n=357	2010–2014 n=371	p
Age	42.1 (±11.3)	44.9 (±12.3)	45.8 (±13.2)	44.9 (±15.3)	0.0185
CPSI pain	11.1 (±4.6)	10.6 (±4.6)	10.2 (±5.1)	10.7 (±5.0)	0.2000
CPSI urination	4.5 (±2.9)	5.1 (±3.0)	4.6 (±3.1)	5.0 (±3.3)	0.0564
CPSI QoL	7.8 (±3.0)	7.7 (±3.0)	7.8 (±3.1)	8.2 (±3.2)	0.2272
CPSI total	23.4 (±8.3)	23.4 (±8.8)	22.7 (±9.2)	23.8 (±9.3)	0.3599
UPOINT					
U	144 (73.8%)	291 (75.2%)	250 (70.0%)	256 (69.0%)	0.0636
P	45 (23.1%)	94 (24.3%)	94 (26.3%)	128 (34.5%)	0.0009
O	67 (34.4%)	175 (45.2%)	224 (62.7%)	194 (52.3%)	<0.0001
I	116 (59.5%)	140 (36.2%)	90 (25.2%)	94 (25.3%)	<0.0001
N	88 (45.1%)	115 (29.7%)	95 (26.6%)	104 (28.0%)	0.0003
T	55 (28.2%)	173 (44.7%)	156 (43.7%)	260 (70.1%)	<0.0001
Pain locations					
Perineum	138 (70.8%)	230 (59.4%)	210 (58.8%)	210 (56.6%)	0.0049
Testicular	95 (48.7%)	215 (55.6%)	163 (45.7%)	185 (49.9%)	0.3924
Tip of penis	57 (29.2%)	137 (35.4%)	115 (32.2%)	132 (35.6%)	0.3195
Pubic/bladder	121 (62.1%)	246 (63.6%)	217 (60.8%)	214 (57.7%)	0.1456
Dysuria	92 (47.2%)	165 (42.6%)	146 (40.9%)	150 (40.4%)	0.1368
Ejaculation	104 (53.3%)	182 (47.0%)	165 (46.2%)	164 (44.2%)	0.0591
Treatment by referring physician*					
Alpha-blockers	64 (32.8%)	244 (63%)	263 (73.7%)	235 (63.3%)	<0.0001
Neuromodulation	16 (8.2%)	45 (11.6%)	79 (22.1%)	95 (25.6%)	<0.0001
Phytotherapy	62 (31.8%)	139 (35.9%)	204 (57.1%)	159 (42.9%)	0.0001
Physiotherapy	13 (6.6%)	21 (5.4%)	13 (3.6%)	36 (9.7%)	0.1078
Antibiotics	53 (27.2%)	82 (21.2%)	82 (23%)	76 (20.5%)	0.1759

*Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic. CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).

along with assessment of failed therapies, resulted in therapeutic strategies that provided favourable patient outcomes by examining this same patient population one year after the first clinic assessment described in the present study.

Conclusion

The increased recognition of the UPOINT P and T domains by referring physicians may be responsible for the changing clinical face of CP/CPPS. This increased recognition of specific domains coincides with increased use of their associated therapies. However, there was little change in pain or urinary symptom patterns and QoL over the 16 years of assessment. The more things “appear” to change, the more they stay the same.

Competing interests: Dr. Nickel has been a consultant for Astellas, Auxilium, Eli Lilly, Farr Labs, Ferring, GSK, Pfizer, Redleaf Pharma, Taris Biomedical, Tribute, and Trillium Therapeutics; a lecturer for Astellas and Eli Lilly; and has participated in clinical trials supported by Eli Lilly, GSK, J&J, Pfizer, and Taris Biomedical. The remaining authors report no competing personal or financial interests related to this work.

Acknowledgements: Dr. Nickel is supported by grants from the CIHR and NIH/NIDDK.

This paper has been peer-reviewed.

References

- Thin RN. The diagnosis of prostatitis: a review. *Genitourin Med* 1991;67:279-83. <https://doi.org/10.1136/sti.67.4.279>
- Roberts RO, Lieber MM, Bostwick DG, et al. A review of clinical and pathological prostatitis syndromes. *Urology* 1997;49:809-21. [https://doi.org/10.1016/S0090-4295\(97\)00235-5](https://doi.org/10.1016/S0090-4295(97)00235-5)
- Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. *JAMA* 1999;282:236-7. <https://doi.org/10.1001/jama.282.3.236>
- Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: Consensus report from the First National Institutes of Health International Prostatitis Collaborative Network. *Urology* 1999;54:229-33. [https://doi.org/10.1016/S0090-4295\(99\)00205-8](https://doi.org/10.1016/S0090-4295(99)00205-8)
- Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. *J Urol* 1999;162:369-75. [https://doi.org/10.1016/S0022-5347\(05\)68562-X](https://doi.org/10.1016/S0022-5347(05)68562-X)
- Wagenlehner FME, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis—chronic pelvic pain syndrome: A multicentre, randomized, prospective, double-blind, placebo-controlled phase 3 study. *Eur Urol* 2009;56:544-51. <https://doi.org/10.1016/j.eururo.2009.05.046>

7. Nickel JC, Pontari M, Moon T, et al. A randomized, placebo-controlled, multicentre study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. *J Urol* 2003;169:1401-5. <https://doi.org/10.1097/01.ju.0000054983.45096.16>
8. Nickel JC, Krieger JN, McNaughton-Collins M, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. *N Engl J Med* 2008;359:2663-73. <https://doi.org/10.1056/NEJMoa0803240>
9. Nickel JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population-based study using the National Institutes of Health Chronic Prostatitis Symptom Index. *J Urol* 2001;165:842-5. [https://doi.org/10.1016/S0022-5347\(05\)66541-X](https://doi.org/10.1016/S0022-5347(05)66541-X)
10. Wagenlehner FME, van Till JWO, Magri V, et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. *Eur Urol* 2013;63:953-9. <https://doi.org/10.1016/j.eururo.2012.10.042>
11. Anothaisintawee T, Attia J, Nickel JC, et al. The management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. *JAMA* 2011;305:78-86. <https://doi.org/10.1001/jama.2010.1913>
12. Shoskes DA, Nickel JC, Dolinga R, et al. Clinical phenotyping of chronic prostatitis/chronic pelvic pain patients and correlation with symptom severity. *Urology* 2009;73:538-43. <https://doi.org/10.1016/j.urolgy.2008.09.074>
13. Nickel JC, Shoskes D. Phenotypic approach to the management of chronic prostatitis/chronic pelvic pain syndrome. *Curr Urol Rep* 2009;10:307-12. <https://doi.org/10.1007/s11934-009-0050-7>
14. Shoskes D, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: A management strategy for urological chronic pelvic pain syndromes. *Prostate Cancer Prostatic Dis* 2009;12:177-83. <https://doi.org/10.1038/pcan.2008.42>
15. Nickel JC. Prostatitis. *Can Urol Assoc J* 2011;5:306-15. <https://doi.org/10.5489/cuaj.686>
16. Rees J, Abrahams M, Doble A, et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: A consensus guideline. *BJU Int* 2015;116:509-25. <https://doi.org/10.1111/bju.13101>
17. Sharp VJ, Takacs EB, Powell CR. Prostatitis: Diagnosis and treatment. *Am Fam Physician* 2010;82:397-406.

Correspondence: Dr. R. Christopher Doiron, Department of Urology, Queen's University, Kingston, ON, Canada; chris.doiron@queensu.ca

Supplementary Table 1. UPOINT associations in 1310 CP/CPPS patients treated at a single outpatient clinic from 1998–2014

	U n=941	P n=361	O n=660	I n=440	N n=402	T n=644
Age	44.8 (±13.3)	44.1 (±13.0)	44.8 (±13.4)	45.9 (±12.4)	43.5 (±12.6)	43.6 (±13.5)
CPSI pain	11.2 (±4.8)	10.8 (±5.1)	11.0 (±4.8)	10.5 (±4.7)	11.0 (±4.9)	11.5 (±4.7)
CPSI urination	6.3 (±2.3)	5.2 (±3.0)	4.9 (±3.2)	4.5 (±3.1)	5.1 (±3.1)	5.1 (±3.2)
CPSI QoL	8.2 (±2.9)	8.4 (±3.1)	8.1 (±3.1)	7.8 (±3.0)	7.9 (±3.2)	8.3 (±8.8)
CPSI total	25.8 (±8.2)	24.4 (±9.1)	24.1 (±9.0)	22.8 (±8.8)	24.0 (±9.3)	24.9 (±8.0)
Pain location						
Perineum	575 (61.1%)	223 (61.8%)	418 (63.3%)	274 (62.3%)	262 (65.2%)	443 (68.8%)
Testicular	503 (53.5%)	191 (52.9%)	344 (52.1%)	217 (49.3%)	223 (55.5%)	356 (55.3%)
Tip of penis	348 (37.0%)	113 (31.3%)	226 (34.2%)	153 (34.8%)	132 (32.8%)	225 (34.9%)
Pubic/bladder	629 (66.8%)	226 (62.6%)	416 (63.0%)	255 (58.0%)	269 (66.9%)	423 (65.7%)
Dysuria	454 (48.2%)	156 (43.2%)	294 (44.5%)	194 (44.1%)	182 (45.3%)	293 (45.5%)
Ejaculation	473 (50.3%)	177 (49.0%)	316 (47.9%)	218 (49.5%)	211 (52.5%)	324 (50.3%)
Treatment by referring physician*						
Alpha-blockers	659 (70.0%)	235 (65.1%)	445 (67.4%)	240 (54.5%)	247 (61.4%)	422 (65.5%)
Antidepressants	150 (15.9%)	105 (29.1%)	109 (16.5%)	54 (12.3%)	65 (16.2%)	121 (18.8%)
Quercetin	304 (32.3%)	115 (31.9%)	244 (37.0%)	158 (35.9%)	151 (37.6%)	227 (35.2%)
QUrol	87 (9.2%)	41 (11.4%)	57 (8.6%)	25 (5.7%)	32 (8.0%)	68 (10.6%)
Gabapentinoids	61 (6.5%)	37 (10.2%)	43 (6.5%)	19 (4.3%)	20 (5.0%)	52 (8.1%)
Acupuncture	8 (0.9%)	8 (2.2%)	5 (0.8%)	3 (0.7%)	2 (0.5%)	5 (0.8%)
Physiotherapy	20 (2.1%)	13 (3.6%)	14 (2.1%)	6 (1.4%)	9 (2.2%)	27 (4.2%)
Antibiotics	216 (23.0%)	72 (19.9%)	167 (25.3%)	113 (25.7%)	100 (24.9%)	144 (22.4%)
Prostate massage	22 (2.3%)	10 (2.8%)	24 (3.6%)	24 (5.5%)	12 (3.0%)	18 (2.8%)

*Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic. CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).

Supplementary Table 2. Associations of number of UPOINT domains in 1310 CP/CPPS patients treated at a single outpatient clinic from 1998–2014

	1	2	3	4	5	6
	n=249	n=408	n=368	n=192	n=39	n=7
Age	45.3 (±14.1)	44.5 (±12.7)	44.3 (±13.2)	44.7 (±13.1)	43.8 (±13.8)	49.4 (±3.3)
CPSI pain	9.2 (±4.6)	10.6 (±4.6)	11.1 (±4.9)	11.6 (±5.2)	11.8 (±4.3)	14.3 (±2.8)
CPSI urination	3.4 (±2.9)	4.6 (±3.1)	5.7 (±3.0)	6.3 (±2.5)	5.4 (±2.8)	6.3 (±1.1)
CPSI QoL	6.9 (±3.1)	7.9 (±3.0)	8.3 (±3.0)	8.4 (±3.1)	8.4 (±2.9)	10.9 (±1.1)
CPSI total	19.5 (±8.2)	23.2 (±8.4)	25.1 (±8.8)	26.4 (±9.1)	25.6 (±8.1)	31.4 (±6.0)
UPOINT						
U	118 (47.4%)	287 (70.3%)	311 (84.5%)	181 (94.3%)	35 (89.7%)	7 (100%)
P	11 (4.4%)	63 (15.4%)	128 (34.8%)	119 (62.0%)	33 (84.6%)	7 (100%)
O	45 (18.1%)	169 (41.4%)	252 (68.5%)	148 (77.1%)	37 (94.9%)	7 (100%)
I	44 (17.7%)	129 (31.6%)	143 (38.9%)	86 (44.8%)	29 (74.4%)	7 (100%)
N	33 (13.3%)	103 (25.2%)	123 (33.4%)	106 (55.2%)	27 (69.2%)	7 (100%)
T	62 (24.9%)	160 (39.2%)	227 (61.7%)	153 (79.7%)	34 (87.2%)	7 (100%)
Pain locations						
Perineum	125 (50.2%)	243 (59.6%)	241 (65.5%)	123 (64.1%)	30 (76.9%)	4 (57.1%)
Testicular	108 (43.4%)	192 (47.1%)	203 (55.2%)	104 (54.2%)	24 (61.5%)	5 (71.4%)
Tip of penis	74 (29.7%)	146 (35.8%)	128 (34.8%)	65 (33.9%)	16 (41.0%)	1 (14.3%)
Pubic/bladder	130 (52.2%)	242 (59.3%)	243 (66.0%)	132 (68.8%)	24 (61.5%)	7 (100%)
Dysuria	85 (34.1%)	166 (40.7%)	177 (48.1%)	91 (47.4%)	23 (59.0%)	3 (42.9%)
Ejaculatory	101 (40.6%)	185 (45.3%)	187 (50.8%)	106 (55.2%)	18 (46.2%)	4 (57.1%)
Treatment by referring physician*						
Alpha-blockers	128 (51.4%)	236 (57.8%)	265 (72.0%)	125 (65.1%)	30 (76.9%)	6 (85.7%)
Antidepressants	23 (9.2%)	53 (13.0%)	70 (19.0%)	37 (19.3%)	12 (30.8%)	2 (28.6%)
Quercetin	83 (33.3%)	139 (34.1%)	137 (37.2%)	62 (32.3%)	11 (28.2%)	3 (42.9%)
QUrol	18 (7.2%)	33 (8.1%)	38 (10.3%)	18 (9.4%)	5 (12.8%)	0 (0%)
Gabapentinoids	13 (5.2%)	17 (4.2%)	25 (6.8%)	16 (8.3%)	5 (12.8%)	1 (14.3%)
Acupuncture	1 (0.4%)	2 (0.5%)	3 (0.8%)	3 (1.6%)	1 (2.6%)	0 (0%)
Physiotherapy	6 (2.4%)	8 (2.0%)	9 (2.4%)	7 (3.6%)	1 (2.6%)	0 (0%)
Antibiotics	48 (19.3%)	98 (24.0%)	84 (22.8%)	48 (25.0%)	8 (20.5%)	2 (28.6%)
Prostate massage	8 (3.2%)	19 (4.7%)	10 (2.7%)	5 (2.6%)	1 (2.6%)	0 (0%)

*Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic. CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).

Supplementary Table 3. Associations of pain locations in 1310 CP/CPPS patients treated at a single outpatient clinic from 1998–2014

	Perineum pain	Testicular pain	Tip of penis pain	Pubic/bladder pain	Dysuria	Ejaculatory pain
	n=788	n=658	n=441	n=798	n=553	n=615
Age	43.9 (±13.0)	43.9 (±12.8)	44.4 (±13.8)	44.1 (±13.6)	44.5 (±13.6)	42.8 (±12.6)
CPSI pain	12.3 (±3.9)	12.8 (±3.7)	13.1 (±3.7)	12.4 (±3.8)	13.0 (±3.8)	12.8 (±3.8)
CPSI urination	5.1 (±3.1)	5.3 (±3.1)	5.6 (±3.1)	5.5 (±3.0)	5.9 (±3.0)	5.4 (±3.1)
CPSI QoL	8.6 (±2.7)	8.7 (±2.7)	8.9 (±2.4)	8.8 (±2.6)	8.8 (±2.6)	8.8 (±2.6)
CPSI total	26.0 (±7.8)	26.9 (±7.5)	27.6 (±7.2)	26.7 (±7.4)	27.6 (±7.5)	27.0 (±7.5)
UPOINT						
U	575 (73.0%)	503 (76.4%)	348 (78.9%)	629 (78.8%)	454 (82.1%)	473 (76.9%)
P	223 (28.3%)	191 (29.0%)	113 (25.6%)	226 (28.3%)	156 (28.2%)	177 (28.2%)
O	418 (53.0%)	344 (52.3%)	226 (51.2%)	416 (52.1%)	294 (53.2%)	316 (51.4%)
I	274 (34.8%)	217 (33.0%)	153 (34.7%)	255 (32.0%)	194 (35.1%)	218 (35.4%)
N	262 (33.2%)	223 (33.9%)	132 (29.9%)	269 (33.7%)	182 (32.9%)	211 (34.3%)
T	443 (56.2%)	356 (54.1%)	225 (51.0%)	423 (53.0%)	293 (53.0%)	324 (52.7%)
Pain locations						
Perineum	788 (100%)	479 (72.8%)	296 (67.1%)	524 (65.7%)	362 (65.5%)	424 (68.9%)
Testicular	479 (60.8%)	658 (100%)	257 (58.3%)	483 (60.5%)	323 (58.4%)	359 (58.4%)
Tip of penis	296 (37.6%)	257 (39.1%)	441 (100%)	308 (38.6%)	280 (50.6%)	263 (42.8%)
Pubic/bladder	524 (66.5%)	483 (73.4%)	308 (69.8%)	798 (100%)	398 (72.0%)	418 (68.0%)
Dysuria	362 (45.9%)	323 (49.1%)	280 (63.5%)	398 (49.9%)	553 (100%)	347 (56.4%)
Ejaculatory	424 (53.8%)	359 (54.6%)	263 (59.6%)	418 (52.4%)	347 (62.7%)	615 (100%)
Treatment by referring physician*						
Alpha-blockers	502 (63.7%)	412 (62.6%)	303 (68.7%)	529 (66.3%)	386 (69.8%)	402 (65.4%)
Antidepressants	136 (17.3%)	108 (16.4%)	72 (16.4%)	140 (17.5%)	98 (17.7%)	103 (16.7%)
Quercetin	311 (39.5%)	242 (36.8%)	168 (38.1%)	298 (37.3%)	210 (38.0%)	239 (38.9%)
QUrol	77 (9.8%)	59 (9.0%)	51 (11.6%)	71 (8.9%)	53 (9.6%)	62 (10.1%)
Gabapentinoids	55 (7.0%)	49 (7.4%)	35 (7.9%)	55 (6.9%)	44 (8.0%)	43 (7.0%)
Acupuncture	7 (0.9%)	4 (0.6%)	2 (0.5%)	6 (0.8%)	4 (0.7%)	6 (1.0%)
Physiotherapy	27 (3.4%)	22 (3.3%)	17 (3.9%)	28 (3.5%)	19 (3.4%)	14 (2.3%)
Antibiotics	183 (23.2%)	142 (21.6%)	88 (20.0%)	179 (22.4%)	121 (21.9%)	138 (22.4%)
Prostate massage	35 (4.4%)	22 (3.3%)	17 (3.9%)	22 (2.8%)	20 (3.6%)	18 (2.9%)

*Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic. CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).